Capital Performance Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$222K Sell
443
-119
-21% -$57.1K 0.01% 279
2026
Q1
$276K Sell
562
-27
-5% -$14.7K 0.02% 351
2025
Q4
$341K Buy
589
+153
+35% +$86.5K 0.02% 287
2025
Q3
$212K Buy
+436
New +$203K 0.03% 305
2025
Q2
Sell
-532
Closed -$265K 317
2025
Q1
$265K Buy
+532
New +$288K 0.06% 178
2024
Q4
Sell
-208
Closed -$129K 2456
2024
Q3
$129K Buy
+208
New +$123K 0.04% 156

Other funds holding TMO

Capital Performance Advisors's TMO Position: Q2 2026 in Review

Capital Performance Advisors reduced its Thermo Fisher Scientific (TMO) stake by 21% in Q2 2026, selling an estimated $57.1K and leaving 443 shares worth $222K. The position accounts for 0.01% of the portfolio, ranked #279.

Capital Performance Advisors first reported a position in TMO in Q3 2024 and has held it in 6 quarters since. The position peaked at $341K in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Capital Performance Advisors held 443 shares of Thermo Fisher Scientific worth $222K as of Q2 2026.
  • Capital Performance Advisors sold 119 Thermo Fisher Scientific shares in Q2 2026, an estimated $57.1K.
  • Thermo Fisher Scientific made up 0.01% of Capital Performance Advisors's portfolio in Q2 2026, its #279 holding.
  • Capital Performance Advisors first reported a position in Thermo Fisher Scientific in Q3 2024 and has held it in 6 quarters since.
  • Capital Performance Advisors's Thermo Fisher Scientific position peaked at $341K in Q4 2025.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.